Review Article
MEDLINE and present here our consideration of the relationship between both diseases (i.e., Sweet's syndrome and MAC).
case RepoRt
A 71-year-old man with bone marrow failure syndrome presented to the local medical facility with preexisting dyspnea on exertion over several years [ Table 1 ]. Chest radiographs indicated the presence of organizing pneumonia or eosinophilic pneumonia, but the patient neglected to follow-up. One year later, he was admitted to a different local medical facility with fever and cough presenting over 1 month. Chest radiography revealed the presence of bilateral ground-glass opacities and reticular shadows on the X-ray film. Tissue histology from a transbronchial lung biopsy (TBLB) indicated the presence of organizing pneumonia, and bacterial infection or lung cryptococcosis was suspected as possible causes. Antibiotics and antifungal agents were administered and his fever decreased, but the fever and wet cough often reoccurred. Antibiotics were administrated repeatedly.
Exanthema on his neck and a corresponding fever appeared during the clinical course, prompting his visit to the Department of Dermatology (University of Ryukyus Hospital, Japan). In this facility, skin biopsy showed classical dermal neutrophilic infiltration without vasculitis, a finding compatible with Sweet's syndrome. Oral steroid therapy at 40 mg/day was started. Although the clinical response was good, skin eruption and a corresponding fever recurred when the steroid dose was tapered. He was then transferred to our department because of the abnormal chest radiography. The chest X-ray and computed tomography (CT) results indicated consolidation with volume loss in the right lower lobe [ Figure 1a and b], suggesting organizing pneumonia or eosinophilic pneumonia. TBLB was performed and the histological findings from the biopsy specimens showed granulated tissues within alveolar ducts and mild alveolar septal thickening with lymphocyte infiltration and interstitial fibrosis. However, the neutrophilic infiltrations were scant [ Figure 2 ]. Methenamine silver staining and Ziehl-Neelsen staining afforded negative results. Therefore, organizing pneumonia associated with Sweet's syndrome was suspected. Prompt treatment with prednisolone (35 mg/day) improved the radiographic chest image. However, the patient's fever and skin eruption both recurred when the prednisolone dose was tapered, and diffuse infiltrates emerged on the chest X-ray when prednisolone was tapered down to 10 mg/day. Therefore, the prednisolone dose was increased to 20-25 mg/day accordingly. The following year, the patient was readmitted to our department with fever (38°C) and a wet cough. We increased the prednisolone dose up to 35 mg/day, and the patient was discharged from the hospital with an improvement in his clinical condition.
Eleven days postdischarge, the patient was transferred back to us with fever (40°C), a wet cough, and difficulty eating and drinking. Chest X-ray and CT revealed bilateral patchy infiltrations with surrounding ground-glass opacities in both lower lung lobes [ Figure 1c and d]. Prednisolone therapy was increased (up to 40 mg) and intravenous meropenem hydrate was prescribed. Three days later, his respiratory condition worsened, and a bronchoscopic examination was performed. TBLB was not performed because of bleeding, and the bronchoalveolar lavage showed nonspecific findings. Prednisolone therapy was increased (up to 70 mg) and an improvement in his clinical condition was observed, but a persistent fever (38°C-39°C) emerged, followed by pancytopenia. Bone marrow biopsy was performed and acid-fast bacilli were observed in the biopsied tissue. Mycobacterium intracellulare was cultured from the patient's bone marrow, blood, feces, and sputum. Based on these results and his clinical course, we concluded that the pulmonary lesion was caused by a disseminated M. intracellulare infection. Rifampicin, ethambutol, and clarithromycin with steroids were administered, and his pulmonary lesions and respiratory signs and symptoms promptly improved in response to the antibiotic and steroid therapy. Later, immunohistological analysis revealed the presence of mycobacterial antigen in the tissue obtained from the second TBLB [ Figure 3 ].
dIscussIon
Sweet's syndrome is reported to be associated with nontuberculous mycobacterial infections (NTMIs). Our review of the English-language literature found that 42 cases of Sweet's syndrome in association with NTMIs have been reported through PubMed since 1992 [ Table 2 ]. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] Most of these cases were associated with RGM [83.3%, Table 3 ]. The residual cases were associated with SGM (16.7%), but only four of them, including the present case, are associated with MAC [9.5%, Table 3 ]. This indicates that the most predominant causal agent is RGM, while MAC, which is slow growing, is a minor causal agent. [5] In our literature review, the NTMIs most commonly associated with Sweet's syndrome involved the cervical lymph nodes [90.5%, Table 3 ]. RGM cases commonly showed lymphadenitis [ Table 2 ]. All SGM cases other than the present case also showed lymphadenitis [ Table 2 : Case 5, 8, 13, 36, 38, 41] . Thus, lymphadenitis may be a characteristic event in Sweet's syndrome associated with NTMIs. In the present case, worsening of pancytopenia and immunosuppression by steroid treatment was observed after mid-2013 [ Table 1 ]. Therefore, lymphadenitis might not be caused by a weakening of the host's immune reaction. Interestingly, MAC is generally responsible for 80% of all nontuberculous mycobacterial lymphadenitis cases. [20] However, cervical lymphadenitis is less frequently observed in RGM infections, but these infections occur predominantly in skin and soft tissues following trauma and Contd...
after surgical or other procedures in patients without underlying complicated diseases. [21, 22] An explanation for this discrepancy has not been established.
In this literature review, the SGM cases showed commonality in their systemic mycobacterial infections [ Table 2 ]. In the present case, systemic M. intracellulare infection developed during corticosteroid therapy for Sweet's syndrome, but the patient did not initially show an obvious local infection during the clinical course. Therefore, the M. intracellulare infection in this patient is thought to have been caused by corticosteroid immunosuppression, as has been shown in the MAC infection cases reported previously [ Table 2 : cases 8 and 13]. One of the cases reported previously (Case 8) emerged during corticosteroid therapy for Sweet's syndrome, [7] while the remaining case (Case 13) had underlying diabetes mellitus. [15] Immunocompromised hosts are readily colonized by opportunistic SGM. [23, 24] Sweet's syndrome patients are susceptible to infection as a result of their underlying disease state (e.g., hematological malignancy and autoimmune disorders) and by the systemic steroid therapy used to treat this syndrome. In fact, the rate of systemic infection is over 50% for all the NTMI cases [ Tables 2 and 3 ]. Hence, MAC might not be a preceding factor for Sweet's syndrome as long as the infection develops after its onset.
The literature shows that subcutaneous lesions associated with Sweet's syndrome have been reported following NTMIs; however, none of the reports has detailed the date of occurrence of Sweet's syndrome, chronologically. Therefore, we determined the date when the NTMIs first occurred in the cases with Sweet's syndrome in chronological order [ Figure 4 ]. Our results identified 28 cases (69.1%) where NTMIs occurred before the onset of Sweet's syndrome, Table 3 and Figure 4 ]. Cases of Sweet's syndrome occurred within 12 months of NTMI, and most cases occurred within 2 months of it [ Figure 4 ]. Thus, NTMI predominantly precedes the onset of Sweet's syndrome, possibly indicating that NTMI is likely to be a trigger for the development of this syndrome.
We wanted to confirm that there was no possibility that an MAC infection was already established before the onset of Sweet's syndrome in the present case, which showed organizing pneumonia from the earliest days of the clinical course. The results of the second transbronchial-biopsied tissue reported that Mycobacterium antigen was under review. This indicates that the patient was infected with MAC before the diagnosis of MAC disease. However, we could not confirm that the causative agent of the initial organizing pneumonia was present before the onset of Sweet's syndrome. A few cases of MAC-associated organizing pneumonia have been reported. [25, 26] Organizing pneumonia often responds well to corticosteroid therapy. [25, 26] Therefore, it is entirely possible that the pulmonary infection was masked by the corticosteroid therapy. In addition, the present case presented a lesion in the middle lobe/lingular lung segment. Bacterial colonization of this site occurs readily because, anatomically, the middle lobe and lingular segment have low clearance. M. avium can form biofilms in the bronchiolar and bronchial mucosa, [27] raising speculation that in the present patient, M. intracellulare had colonized the organized lesion.
Literature searches show that erythematous lesions in Sweet's syndrome appear primary in the upper extremities (head and neck), and lower extremity lesions are infrequent. [22, 28, 29] The involvement of the head and neck for any Sweet's syndrome category is over 50%. [30] In addition, Sweet's syndrome is accompanied by pharyngeal pain as a predominant symptom. [31] Sweet's syndrome is associated with hypersensitivity to streptococcal antigen, [32] and oral ulcers were reported in 60 of 198 cases (30%) with Sweet's syndrome. [31] Femiano et al. reported that mouth ulcers were preceded by acute tonsillitis. [33] These dermatosis-related oral ulcers typically resolved after initiation of systemic corticosteroid treatment, [33, 34] and tonsillectomy led to an improvement in Sweet's syndrome. [35, 36] These findings indicate the possibility of the tonsils being the focal point of infection and the etiological agents include RGM.
Sweet's syndrome is often associated with immune disorders involving anti-interferon gamma (IFN-γ) autoantibodies, as well as bone marrow dysplasia and auto-inflammatory diseases [ Table 2 ]; [10, 28, 37, 38] however, it is not known exactly how they affect the onset of erythematous lesions in Sweet's syndrome. Sweet's syndrome is generally regarded as a hypersensitive reaction to bacteria, viral, or tumor antigens. Inappropriate secretion of endogenous chemokines and cytokines against such antigens may contribute to the initiation and propagation of the inflammatory response in Sweet's syndrome. [39] Granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) have been implicated in granulocyte activation and they enhance the function of mature neutrophils. [40, 41] In patients with Sweet's syndrome, serum type 1 helper T-cell (Th1) cytokine levels including interleukin (IL)-1α, IL-1 β, IL-2, and IFN-γ are elevated, whereas type 2 helper T cell (Th2)-related cytokine IL-4 levels remain normal. [42] Reuss-Borst et al. reported that IL-6 and G-CSF serum levels were maximally high during the acute phase of the disease, but IL-1β and IFN-γ serum levels were not elevated. [43] Marzano et al. reported that tumor-necrosis-factor (TNF)-α was moderately high and that IL-8 and IL-17 were slightly high in Sweet's syndrome patients compared with the same values in normal controls. [44] Thus, the cytokine secretion pattern during the immune response in Sweet's syndrome differs in each study. We consider that the secretion pattern may be dictated by the preceding causal agent and the immune status of the host. For example, the Th1-type immune response (IL-1α, IL-12, GM-CSF, and TNF-α) is predominant following mycobacterial infection. [45] [46] [47] [48] Mycobacterium chelonae (categorized as RGM) induces IL-8 from macrophages. [49] It is known that immunity in immunocompromised hosts shifts to a Th2-type response. Therefore, NTMIs preceding Sweet's syndrome may induce a dominant Th1-type immune response and the established immunological deterioration may induce dominancy in Th2-type immunity during the clinical course of Sweet's syndrome.
conclusIon
The occurrence of systemic MAC disease may be an inevitable consequence of long-term steroid use and the presence of underlying diseases (e.g., hematological malignancy such as myelodysplastic syndrome, other malignancies, and anti-IFN-γ autoantibodies). If the appearance of MAC disease is lymphadenitis, it will be clinically straightforward to confirm that MAC disease is a contributing factor in Sweet's disease. Cervical lymphadenitis caused by MAC and local infection with RGM often develops in the absence of impaired immunity. However, if the appearance is systemic infection, it will be difficult to clinically confirm that MAC disease is a contributing factor in Sweet's syndrome.
